StandoutStocks.com: "Stocks that Standout" picks for today are: BAX, GTIV, OCLS, TLAN

Jul 13, 2009 (M2 PRESSWIRE via COMTEX) -- TLAN | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" picks for today are: Baxter International Inc. (NYSE: BAX), Gentiva Health Services, Inc. (NASDAQ: GTIV), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Talent Alliance, Inc. (PINKSHEETS: TLAN)

<< << <<

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354

<< << <<

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

<< << <<

Jul 13, 2009 -- Baxter International Inc. (NYSE: BAX | Quote | Chart | News | PowerRating) and Flamel Technologies, SA (NASDAQ: FLML) announced today that they have entered into agreement to formulate controlled release applications of blood clotting factor replacement therapies using Flamel's Medusa(R) Technology. The work between the two companies will focus on developing longer-acting formulations with the objective of reducing the frequency of infusions required to treat blood clotting disorders in hemophilia. Pursuant to the agreement between the two companies, Flamel will receive technology access fees totaling EUR 2.5 million. Baxter will pay all development costs for the program and have an exclusive right to negotiate a license to the Medusa platform.

"We continue to develop and advance novel therapies that improve patient convenience by decreasing the frequency of infusions to help people living with hemophilia lead a more normal life," said Hartmut J. Ehrlich, MD, vice president of global research and development in BioScience at Baxter. "We look forward to this partnership using Flamel's Medusa(R) Technology as a novel approach to address this goal."

"We are pleased to be working with Baxter to develop longer-acting formulations of factor replacement therapies for hemophilia patients," said Stephen H. Willard, Flamel's chief executive officer. "Baxter is an ideal partner for these molecules due to its extensive expertise in the field. Our work with Baxter allows us to leverage our expertise in drug delivery to create solutions for the administration of intravenous formulations of therapeutic proteins. This program has the potential to develop more convenient solutions for people living with hemophilia, their families, and physicians."

About Hemophilia

There are two types of hemophilia: hemophilia A (sometimes called classical hemophilia) and hemophilia B (sometimes called Christmas disease). Both are caused by a low level or absence of one of the proteins in the blood (called factors) that control bleeding. Hemophilia A is caused by a deficiency of factor VIII, and hemophilia B is caused by a deficiency of factor IX.

There is no difference between the two types of hemophilia, except that hemophilia B is about five times less common than hemophilia A. According to the World Federation of Hemophilia, more than 400,000 people in the world have hemophilia.

About Medusa

The Medusa platform uses biodegradable polymers to adsorb therapeutic large molecules through hydrophobic interaction, with no loss of bioactivity, for controlled release applications. The Medusa polymer is amphiphilic and spontaneously forms stable nanoparticles in water. They are robust over a wide range of pH values and can be stored as either stable liquid or stable dry forms that can be easily reconstituted in water.

About Flamel Technologies

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides and other molecules, without reduction in bioactivity. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs; it is the intellectual platform licensed by GlaxoSmithKline for COREG CR(R).

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

<< << <<

Jul 13, 2009 -- Gentiva Health Services, Inc. (NASDAQ: GTIV), a leading provider of comprehensive home health services, announced today that it has scheduled a conference call and web cast on Thursday, July 30, 2009, at 10:00 a.m. ET to discuss operating results for the second quarter ended June 28, 2009. Gentiva plans to issue its financial news release the morning of July 30 before pre-market trading.

The conference call is open to investment analysts and managers, Company shareholders and others interested in Gentiva Health Services. Instructions for participation in the conference call follow:

-- Event: Gentiva Health Services' second quarter 2009 conference call.

-- Date and Time: Thursday, July 30, 2009, 10:00 a.m. ET.

-- Instructions: Participants in the United States, Canada and international locations may call (973) 935-2408 and reference call #19324792.

-- Web Cast URL: http://investors.gentiva.com/events.cfm.

-- Replay: A replay of the call will be available on July 30, beginning at approximately 1 p.m. ET, and will remain available continuously through August 6. To listen to a replay of the call from the United States, Canada or international locations, dial (800) 642-1687 or (706) 645-9291 and enter the following PIN at the prompt: 19324792. Visit http://investors.gentiva.com/events.cfm to access the web cast archive.

-- Transcript: A transcript of the call, including questions and answers, is expected to be available on Gentiva's web site within 48 hours after its conclusion.

About Gentiva Health Services, Inc.

Gentiva Health Services, Inc. is a leading provider of comprehensive home health services, delivering innovative, high-quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; respiratory therapy and home medical equipment; infusion therapy services; and other therapies and services.

<< << <<

Jul 13, 2009 -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to treat infections in chronic and acute wounds, announced today it has entered into an agreement with OroScience, Inc. Under the terms of this agreement, OroScience, Inc. was granted exclusive rights to market Microcyn-based oral products in the U.S., Canada and European professional dental and oral care markets while providing Oculus with a significant percentage of those revenues.

OroScience will support all regulatory, clinical, sales and marketing related to the Microcyn-based professional oral care products with the first product launch anticipated in 2010. The initial products will only require FDA 510(k) clearances. Oculus' R&D team has developed multiple dental-specific formulations of the Microcyn Technology, initially for the prescription market, which can also readily be translated into products for the over-the-counter oral care space.

"We've identified a number of professional dental and oral care product opportunities for the Microcyn Technology, with one Microcyn-based product opportunity having an estimated addressable U.S. market on the order of $500 million," said Mark Fontenot, ME, MBA, DDS, and CEO of OroScience. "We believe our planned suite of Microcyn-based products will bring significant patient benefit for several important conditions such as oral manifestations of diabetes and oral mucositis, secondary to chemotherapy and/or radiotherapy. Our intent is to utilize our broad reach of national distribution partners to achieve timely and ubiquitous distribution."

While Oculus and OroScience will work in concert to develop the products, Oculus is able to offer these formulations to its current and future partners or distributors outside the geographies covered by the agreement, including China, Mexico, India and select Middle East countries.

"While Oculus has focused on building market awareness and sales in the global wound care market, we've also talked of the breadth of Microcyn Technology opportunities beyond wound care including dental, animal healthcare, ophthalmology, respiratory infections and others. This agreement with a proven innovator certainly validates both the applicability of Microcyn Technology in the professional dental space as well as the soundness of our strategy to grow through key partnerships," said Hoji Alimi, founder and CEO of Oculus. "The beauty of this dental partnership is that these new oral care revenues will be in addition to $45 to $60 million guidance for fiscal year 2013. This new partnership allows us to build even greater value for our shareholders without incurring additional expenses."

About OroScience, Inc.

OroScience is a global oral care life science company providing advanced therapies for accelerated wound healing and treatment of oral diseases. OroScience's innovative new products and technologies are created in collaboration with leading dental professionals striving to provide their patients with optimal solutions for managing their acute and chronic oral conditions. OroScience continues to successfully launch innovative new products that represent fundamental change. Learn more about OroScience by visiting the company web site.

OroScience, Inc. is a wholly owned subsidiary of OroScience plc.

About Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

<< << <<

Jul 10, 2009 -- Talent Alliance, Inc. (PINKSHEETS: TLAN | Quote | Chart | News | PowerRating) announced today that it has executed a Letter of Intent to jointly market its TalentExchange platform in China with one of China's leading recruitment firms, Global Talent. Through the partnership, the companies will bring together two cutting edge technologies into a single offering designed to improve efficiencies in the talent acquisition process, and jointly market and promote them in China.

"The partnership with Global Talent is a tremendous win for our business in China," said Brian Davis, CEO of Talent Alliance. "We have done much more that select a marketing partner; we entered into strategic relationship with one of the most progressive and forward thinking recruitment groups in China. We will bring together Global Talent's CloudATS and our TalentExchange products to offer a solution to employers and recruiters not currently available anywhere on the market. Global Talent brings with it a portfolio of large clients in China and we add this exclusive technology to the mix for a great potential channel for rapid expansion in China."

The ChinaTalentExchange(r) and Global Talent's CloudATS are both currently live and operating independently but will be brought together by a joint development process. The TalentExchange marketplace supports and greatly streamlines the hiring process for companies and improves the marketing and submission process for recruiters. ChinaTalentExchange is free to register and any fees associated with the successful hire of a candidate only occur on a contingency basis with a full money back guarantee to the employers.

About Talent Alliance

Based in Austin, Texas and Shanghai, China -- Talent Alliance, Inc. provides talent management and talent acquisition technology applications and resources in the United States and The People's Republic of China. Talent Alliance provides world class permanent placement recruiting, contingent staffing, employee leasing and benefits management services, and proprietary talent acquisition technology solutions to small, medium sized businesses and multi-national corporations in the United States and the People's Republic of China. The company currently has offices in Texas, Florida, California, and Shanghai and Beijing, China.

<< << <<

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index